The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
Abstract
In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has received enthusiastic investigation, and significant progress has been made toward understanding its tumorigenic role and clinical significance. Among various thyroid tumors, this mutation occurs uniquely in papillary thyroid cancer (PTC), the most common endocrine malignancy, and some apparently PTC-derived anaplastic thyroid cancers. Many studies have found this mutation to be associated with those clinicopathological characteristics of PTC that are conventionally known to predict tumor progression and recurrence, including, for example, old patient age, extrathyroidal invasion, lymph node metastasis, and advanced tumor stages. Direct association of BRAF mutation with the clinical progression, recurrence, and treatment failure of PTC has also been demonstrated. The BRAF mutation has even been correlated with PTC recurrence in patients with conventionally low-risk clinicopathological factors. Some molecular mechanisms determining BRAF mutation-promoted progression and the aggressiveness of PTC have recently been uncovered. These include the down-regulation of major tumor suppressor genes and thyroid iodide-metabolizing genes and the up-regulation of cancer-promoting molecules, such as vascular endothelial growth factor, matrix metalloproteinases, nuclear transcription factor kappaB, and c-Met. Thus, BRAF mutation represents a novel indicator of the progression and aggressiveness of PTC. Significant advances have also occurred in the preclinical testing of new therapeutic strategies targeting the MAPK pathway aberrantly activated by BRAF mutation and other related mutations. New mitogen extracellular kinase (MEK) inhibitors developed recently are particularly promising therapeutic agents for thyroid cancer. With these advances, it has become clearer that BRAF mutation will likely have significant impact on the clinical management of PTC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
microRNAs as oncogenes and tumor suppressors
Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2006.08.028 · Cited by 2,749
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Self-citationTargeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
Molecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Xing, M., Alzahrani, A. S., Carson, K. A., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., et al. (2013) · JAMA · doi:10.1001/jama.2013.3190 · Cited by 940
Self-citationXing, M., Liu, R., Liu, X., Murugan, A. K., Zhu, G., Zeiger, M. A., Pai, S., & Bishop, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5094 · Cited by 725
Self-citationMolecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules
Nikiforov, Y. E., Steward, D. L., Robinson-Smith, T. M., Haugen, B. R., Klopper, J. P., Zhu, Z., Fagin, J. A., Falciglia, M., Weber, K., & Nikiforova, M. N. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0247 · Cited by 711
Progress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Self-citationRicarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0727 · Cited by 529
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., Romei, C., Miccoli, P., Pinchera, A., & Basolo, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0607 · Cited by 528
Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
Xing, M., Alzahrani, A. S., Carson, K. A., Shong, Y. K., Kim, T. Y., Viola, D., Elisei, R., Bendlová, B., Yip, L., Mian, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.8253 · Cited by 523
Self-citationTERT promoter mutations in thyroid cancer
Liu, R., & Xing, M. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0533 · Cited by 441
Self-citationKim, T. H., Park, Y. J., Lim, J. A., Ahn, H. Y., Lee, E. K., Lee, Y. J., Kim, K. W., Hahn, S. K., Youn, Y. K., Kim, K. H., et al. (2012) · Cancer · doi:10.1002/cncr.26500 · Cited by 400
Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Self-citationMontero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., Ryder, M., Ghossein, R. A., Rosen, N., & Fagin, J. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0531 · Cited by 382
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Jung, C. K., Little, M. P., Lubin, J. H., Brenner, A. V., Wells, S. A., Sigurdson, A. J., & Nikiforov, Y. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2503 · Cited by 343
Liu, X., Qu, S., Liu, R., Sheng, C., Shi, X., Zhu, G., Murugan, A. K., Guan, H., Yu, H., Wang, Y., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4048 · Cited by 318
Self-citationMolecular Diagnostics and Predictors in Thyroid Cancer
Nikiforova, M. N., & Nikiforov, Y. E. (2009) · Thyroid · doi:10.1089/thy.2009.0240 · Cited by 309
Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
Xing, M. (2010) · Thyroid · doi:10.1089/thy.2010.1646 · Cited by 305
Self-citationTufano, R. P., Teixeira, G. V., Bishop, J., Carson, K. A., & Xing, M. (2012) · Medicine · doi:10.1097/md.0b013e31826a9c71 · Cited by 302
Self-citationLiu, R., Bishop, J., Zhu, G., Zhang, T., Ladenson, P. W., & Xing, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3288 · Cited by 296
Self-citationMolecular Diagnostics of Thyroid Tumors
Nikiforov, Y. E. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0664-rair.1 · Cited by 257
Senescent tumor cells lead the collective invasion in thyroid cancer
Kim, Y. H., Choi, Y. W., Lee, J., Soh, E. Y., Kim, J.-H., & Park, T. J. (2017) · Nature Communications · doi:10.1038/ncomms15208 · Cited by 253
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
Oh, J. M., & Ahn, B.-C. (2021) · Theranostics · doi:10.7150/thno.57689 · Cited by 163
Johnson, G. L., Stuhlmiller, T. J., Angus, S. P., Zawistowski, J. S., & Graves, L. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1081 · Cited by 129
Bommarito, A., Richiusa, P., Carissimi, E., Pizzolanti, G., Rodolico, V., Zito, G., Criscimanna, A., Di Blasi, F., Pitrone, M., Zerilli, M., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0076 · Cited by 70
Kim, H. J., Park, H. K., Byun, D. W., Suh, K., Yoo, M. H., Min, Y.-K., Kim, S. W., & Chung, J. H. (2018) · European Journal of Nutrition · doi:10.1007/s00394-016-1370-2 · Cited by 60
Investigation of BRAFand CTNNB1 activating mutations in adrenocortical tumors
Masi, G., Lavezzo, E., Iacobone, M., Favia, G., Palù, G., & Barzon, L. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346515 · Cited by 29
Xie, J., Liu, J., Zhao, M., Li, X., Wang, Y., Zhao, Y., Cao, H., Ji, M., Chen, M., & Hou, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043418 · Cited by 29
Kim, M., Kim, S.-J., Xu, Z., Ha, S. Y., Byeon, J. H., Kang, E. J., Shin, S.-H., Yoo, S.-K., Jee, H.-G., Yoon, S. G., et al. (2020) · Thyroid · doi:10.1089/thy.2019.0301 · Cited by 11
Rethinking the role of oncogenes in papillary thyroid cancer initiation
Vitale, M. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00083 · Cited by 10
Metadata
- Authors
- Xing, M.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2007-10-16
- Volume
- 28
- Issue
- 7
- Pages
- 742-762
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2101888941
- Cited by
- 983
- References
- 160
- FWCI
- 31.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.